Literature DB >> 28472496

Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.

Yasmine Zerdoumi1, Raphaël Lanos1, Sabine Raad1, Jean-Michel Flaman1, Gaëlle Bougeard1, Thierry Frebourg1, Isabelle Tournier1.   

Abstract

Entities:  

Year:  2017        PMID: 28472496      PMCID: PMC5886279          DOI: 10.1093/hmg/ddx165

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


× No keyword cloud information.
Human Molecular Genetics, 2017, 26, 2591--2602. The Publishers would like to apologize for an error in the list of funders for the above paper. The correct funding statement is the following: This work was supported by the French National Cancer Institute (INCa), the French Association for Cancer Research (Fondation ARC), the League against cancer (Ligue contre le Cancer) and by the European Regional Development Fund (European Union and Région Normandie). Funding to pay the Open Access publication charges for this article was provided by the French Institute for Health and Medical Research (Inserm). This has been corrected online and in print.
  5 in total

1.  p53 mutation in normal esophagus promotes multiple stages of carcinogenesis but is constrained by clonal competition.

Authors:  Kasumi Murai; Stefan Dentro; Swee Hoe Ong; Roshan Sood; David Fernandez-Antoran; Albert Herms; Vasiliki Kostiou; Irina Abnizova; Benjamin A Hall; Moritz Gerstung; Philip H Jones
Journal:  Nat Commun       Date:  2022-10-20       Impact factor: 17.694

2.  Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.

Authors:  Kelvin C de Andrade; Megan N Frone; Talia Wegman-Ostrosky; Payal P Khincha; Jung Kim; Amina Amadou; Karina M Santiago; Fernanda P Fortes; Nathanaël Lemonnier; Lisa Mirabello; Douglas R Stewart; Pierre Hainaut; Luiz P Kowalski; Sharon A Savage; Maria I Achatz
Journal:  Hum Mutat       Date:  2018-11-19       Impact factor: 4.878

3.  Li-Fraumeni Syndrome in the Cancer Genomics Era.

Authors:  William D Foulkes; Paz Polak
Journal:  J Natl Cancer Inst       Date:  2021-07-07       Impact factor: 11.816

4.  Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.

Authors:  Elisabeth Jarhelle; Hilde Monica Frostad Riise Stensland; Geir Åsmund Myge Hansen; Siri Skarsfjord; Christoffer Jonsrud; Monica Ingebrigtsen; Nina Strømsvik; Marijke Van Ghelue
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

Review 5.  What 20 years of research has taught us about the TP53 p.R337H mutation.

Authors:  Emilia Modolo Pinto; Gerard P Zambetti
Journal:  Cancer       Date:  2020-08-17       Impact factor: 6.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.